medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2021, Número 4

<< Anterior Siguiente >>

Dermatología Cosmética, Médica y Quirúrgica 2021; 19 (4)


SARS-COV-2: la piel y sus anexos a un año del inicio de la pandemia

Cano ALE, Briseño GG, Barrera OCA, Hernández ZC, Milián SX, Vega MME

Idioma: Español
Referencias bibliográficas: 83
Paginas: 382-391
Archivo PDF: 218.12 Kb.


RESUMEN

La pandemia por el nuevo betacoronavirus comenzó el 11 de marzo de 2020. Este virus es capaz de afectar al sistema respiratorio, digestivo, neurológico, hepático, cardiaco y cutáneo. En relación con la afección mucotegumentaria se han reportado múltiples casos clínicos en piel, uñas, mucosa oral y genital, así como en el pelo y la piel cabelluda en adultos y pacientes pediátricos. Se revisó la evidencia publicada de las manifestaciones en la piel y anexos relacionadas con la infección por SARS-COV-2 en la base de datos PubMed. En esta revisión se plantean nuevos conceptos en comparación con publicaciones previas, como las múltiples hipótesis de afectación vasculocutánea, los hallazgos histopatológicos reportados, daño de anexos cutáneos, pruebas de diagnóstico, tratamiento y las secuelas cutáneas. El estudio de la piel ha sido un protagonista esencial durante la observación de las manifestaciones clínicas de la infección por SARSCOV- 2, por lo que conocer la literatura publicada alrededor del mundo es de vital importancia en nuestra práctica médica para identificar marcadores cutáneos potenciales de diagnóstico o que se presenten durante la evolución de la enfermedad.
El objetivo principal es revisar las publicaciones internacionales de las alteraciones de la piel y anexos relacionadas con la infección por SARS-COV-2 a un año de su declaración como pandemia, con el fin de aumentar el umbral de sospecha de infección y poder referir al paciente de manera temprana para la atención médica profesional.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kaur I, Sharma A, Jakhar D, Das A, Aradhya SS, Sharma R, Jindal V y Mhatre M, Coronavirus disease (covid-19): an updated review based on current knowledge and existing literature for dermatologists, Dermatol Ther 2020; 33(4):e13677.

  2. https://www.who.int/dg/speeches/detail/who-director-general-sopening- remarks-at-the-media-briefing-on-covid-19-11-march-2020.

  3. Novel coronavirus (covid-19) cases, provided by covid-19 data repository by the Center for Systems Science and Engineering (csse) at Johns Hopkins University. Disponible en: systems.jhu.edu/research/ public-health/ncov.

  4. García-Legaz Martínez M, Martínez-Doménech Á, Magdaleno-Tapial J, Valenzuela-Oñate C, Partarrieu-Mejías F, Lorca-Spröhnle J et al., Acute acral cutaneous manifestations during the covid-19 pandemic: a singlecentre experience, J Eur Acad Dermatol Venereol 2020; 34(11):e692-4.

  5. Guan W, Ni Z, Hu Y et al., Clinical characteristics of coronavirus disease 2019 in China, Emerg Med 2020; 58(4):711-2.

  6. Gianotti R, Zerbi P y Dodiuk-Gad RP, Clinical and histopathological study of skin dermatoses in patients affected by covid-19 infection in the Northern part of Italy, J Dermatol Sci 2020; 98(2):141-3.

  7. Xue X, Mi Z, Wang Z, Pang Z, Liu H y Zhang F, High expression of ace2 on keratinocytes reveals skin as a potential target for sars-cov-2, J Invest Dermatol 2021; 141(1):206-9.e1.

  8. Bessis D, Impaired type i interferon response in sars-cov-2 infection: looking through the cutaneous window, Br J Dermatol 2021; 184(1):11-2.

  9. Garg S, Garg M, Prabhakar N, Malhotra P y Agarwal R, Unraveling the mystery of covid-19 cytokine storm: from skin to organ systems, Dermatol Ther 2020; 33(6):e13859.

  10. Rubin A, Alamgir M, Rubin J y Rao BK, Chilblain-like lesions with prominent bullae in a patient with covid-19, bmj Case Rep 2020; 13(11):e237917.

  11. Macedo-Pérez M, Barragán-Estudillo ZF, Castillo-Montúfar E, Choi SJ, Fernández-Rueda P et al., Dermatological findings in covid-19 patients: Mexican experience, Int J Dermatol 2020; 59(7):872-3.

  12. Visconti A, Bataille V, Rossi N, Kluk J, Murphy R, Puig S, Nambi R, Bowyer RC, Murray B, Bournot A, Wolf J, Ourselin S, Steves CJ, Spector TD y Falchi M, Diagnostic value of cutaneous manifestation of sarscov- 2 infection, Br J Dermatol 2021; 184(5):880-7.

  13. Galván Casas C, Català A, Carretero Hernández G, Rodríguez-Jiménez P, Fernández-Nieto D, Rodríguez-Villa Lario A et al. Classification of the cutaneous manifestations of covid-19: a rapid prospective nationwide consensus study in Spain with 375 cases, Br J Dermatol 2020; 183(1):71-7.

  14. Fernández-Nieto D, Jiménez-Cauhe J, Ortega-Quijano D, Diaz- Guimarãens B, Domínguez-Santás M et al., Transverse leukonychia (Mee’ lines) nail alterations in a covid-19 patient, Dermatol Ther 2020; 33(6):e13863.

  15. Ide S, Morioka S, Inada M y Ohmagari N, Beau’s lines and leukonychia in a covid-19 patient, Intern Med 2020; 59(24):3259.

  16. Neri I, Guglielmo A, Virdi A, Gaspari V, Starace M y Piraccini BM, The red half-moon nail sign: a novel manifestation of coronavirus infection, J Eur Acad Dermatol Venereol 2020; 34(11):e663-5.

  17. Senturk N y Ozdemir H, Onychomadesis following covid-19 infection: is there a relationship?, Dermatol Ther 2020; 33(6):e14309.

  18. Goren A, Vaño-Galván S, Wambier CG, McCoy J, Gómez-Zubiaur A, Moreno-Arrones OM et al., A preliminary observation: male pattern hair loss among hospitalized covid-19 patients in Spain: a potential clue to the role of androgens in covid-19 severity, J Cosmet Dermatol 2020; 19(7):1545-7.

  19. McCoy J, Wambier CG, Vaño-Galván S, Shapiro J, Sinclair R, Ramos PM et al., Racial variations in covid-19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti-androgens a potential treatment for covid-19?, J Cosmet Dermatol 2020; 19(7):1542-3.

  20. Wambier CG, Vaño-Galván S, McCoy J, Gómez-Zubiaur A, Herrera S, Hermosa-Gelbard Á et al., Androgenetic alopecia present in the majority of patients hospitalized with covid-19: the “Gabrin sign”, J Am Acad Dermatol 2020; 83(2):680-2.

  21. Wambier CG, Vaño-Galván S, McCoy J, Pai S, Dhurat R y Goren A, Androgenetic alopecia in covid-19: compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign, J Am Acad Dermatol 2020; 83(6):453-4.

  22. Rizzetto G, Diotallevi F, Campanati A, Radi G, Bianchelli T, Molinelli E et al., Telogen effluvium related to post severe sars-cov infection: clinical aspects and our management experience, Dermatol Ther 2021; 34(1):1-16.

  23. Moreno-Arrones OM, Lobato-Berezo A, Gómez-Zubiaur A, Arias- Santiago S, Saceda-Corralo D, Bernárdez-Guerra C et al., sars-cov induced telogen effluvium: a multicentric study, J Eur Acad Dermatol Venereol 2020; 35(3):181-3.

  24. Cline A, Kazemi A, Moy J, Safai B y Marmon S, A surge in the incidence of telogen effluvium in minority predominant communities heavily impacted by covid-19, J Am Acad Dermatol 2021; 84(3)773-5.

  25. Domínguez-Santás M, Haya-Martínez L, Fernández-Nieto D, Jiménez- Cauhé J, Suárez-Valle A y Diaz-Guimarãens B, Acute telogen effluvium associated with sars-cov-2 infection, Aust J Gen Pract 2020; 49(1):1-2.

  26. Rivetti N y Barruscotti S, Management of telogen effluvium during the covid-19 emergency: psychological implications, Dermatol Ther 2020; 33(4):1-5.

  27. Mieczkowska K, Deutsch A, Borok J, Guzmán AK, Fruchter R, Patel P et al., Telogen effluvium: a sequela of covid-19, Int J Dermatol 2021; 60(1):122-4.

  28. Olds H, Liu J, Luk K, Lim HW, Ozog D y Rambhatla PV, Telogen effluvium associated with covid-19 infection, Dermatol Ther 2021; 6:1-4.

  29. Trüeb RM, Dutra Rezende H y Gavazzoni Dias MFR, What can the hair tell us about covid-19?, Exp Dermatol 2021; 30(2):288-90.

  30. Kutlu Ö, Aktas, H, I . mren IG y Metin A., Short-term stress-related increasing cases of alopecia areata during the covid-19 pandemic, J Dermatolog Treat 2020; 19:1.

  31. Martín Carreras-Presas C, Amaro Sánchez J, López-Sánchez AF, Jané- Salas E y Somacarrera Pérez ML, Oral vesiculobullous lesions associated with sars-cov-2 infection, Oral Dis 2020. doi:10.1111/odi.13382.

  32. Magro C, Mulvey JJ, Berlin D et al., Complement associated microvascular injury and thrombosis in the pathogenesis of severe covid-19 infection: a report of five cases, Transl Res 2020; 220:1-13.

  33. Nuño-González A, Martín-Carrillo P, Magaletsky K, Martín Ríos MD, Herranz Mañas C, Artigas Almazán J et al., Prevalence of mucocutaneous manifestations in 666 patients with covid-19 in a field hospital in Spain: oral and palmoplantar findings, Br J Dermatol 2021; 184(1):184-5.

  34. Aghazadeh N, Homayouni M y Sartori-Valinotti JC, Oral vesicles and acral erythema: report of a cutaneous manifestation of covid-19, Int J Dermatol 2020; 59(9):1153-4.

  35. Soares CD, Carvalho RA, Carvalho KA, Carvalho MG y Almeida OP, Letter to Editor: Oral lesions in a patient with covid-19, Med Oral Patol Oral Cir Bucal 2020; 25(4):e563-4.

  36. Binois R, Colin M, Rzepecki V, Prazuck T, Esteve E y Hocqueloux L, A case of erythema multiforme major with multiple mucosal involvements in covid-19 infection, Int J Dermatol 2021; 60(1):117-8.

  37. Domínguez-Santás M, Diaz-Guimarãens B, Fernández-Nieto D, Jiménez-Cauhe J, Ortega-Quijano D y Suárez-Valle A, Minor aphthae associated with sars-cov-2 infection, Int J Dermatol 2020; 59(8): 1022-3.

  38. Soares CD, Mosqueda-Taylor A, De Carvalho MGF y De Almeida OP, Oral vesiculobullous lesions as an early sign of covid-19: immunohistochemical detection of sars-cov-2 spike protein, Br J Dermatol 2021; 184(1):e6.

  39. Rekhtman S, Tannenbaum R, Strunk A, Birabaharan M, Wright S y Garg A, Mucocutaneous disease and related clinical characteristics in hospitalized children and adolescents with covid-19 and multisystem inflammatory syndrome in children, J Am Acad Dermatol 2021; 84(2):408-14.

  40. Chaux-Bodard AG, Deneuve S y Desoutter A, Oral manifestation of covid-19 as an inaugural symptom?, J Oral Med Oral Surg 2020; 26:18.

  41. Freeman EE, McMahon DE, Hruza GJ, Lipoff JB, French LE, Fox LP y Fassett MS, Timing of pcr and antibody testing in patients with covid- 19 associated dermatologic manifestations, J Am Acad Dermatol 2021; 84(2):505-7.

  42. Colmenero I, Santonja C, Alonso-Riaño M, Noguera-Morel L, Hernández- Martín A et al., sars-cov-2 endothelial infection causes covid-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases, Br J Dermatol 2020; 183(4):729-37.

  43. Jamiolkowski D, Mühleisen B, Müller S, Navarini AA, Tzankov A y Roider E, sars-cov-2 pcr testing of skin for covid-19 diagnostics: a case report, The Lancet 2020; 396(10251):598-9.

  44. Fattori A, Cribier B, Chenard MP, Mitcov M, Mayeur S y Weingertner N, Cutaneous manifestations in patients with coronavirus disease 2019: clinical and histological findings, Hum Pathol 2021; 107:39-45.

  45. Li H, Zhao Y, Zhou L y Hu J, Cutaneous, skin histopathological manifestations and relationship to covid-19 infection patients, Dermatol Ther 2020; 33(6):e14157.

  46. Barker-Davies RM, O’Sullivan O, Senaratne KPP, Baker P, Cranley M, Dharm-Datta S et al., The Stanford Hall consensus statement for postcovid- 19 rehabilitation, Br J Sports Med 2020; 54(16):949-59.

  47. Temiz SA y Kutlu Ö, The development of dermatologic diseases in patients recovered from covid-19, Dermatol Ther 2021; 23:e14791.

  48. Krammer F, sars-cov-2 vaccines in development, Nature 2020; 586:516-27.

  49. Galván-Casas C, Català A y Muñoz-Santos C, sars-cov-2 vaccines and the skin, Actas Dermosifiliogr 2021. doi: 10.1016/j.ad.2021.05.011.

  50. Rumbo-Prieto JM, Reacciones cutáneas asociadas a la vacuna covid, ¿qué sabemos?, Enferm Dermatol 2021; 15(42):6-7.

  51. Kempf W, Kettelhack N, Kind F, Courvoisier S, Galambos J y Pfaltz K, “covid-arm”: histological features of a delayed-type hypersensitivity reaction to Moderna mrna-1273 sars-cov-2 vaccine, J Eur Acad Dermatol Venereol 2021. doi: 10.1111/jdv.17506.

  52. Wei N, Fishman M, Wattenberg D, Gordon M y Lebwohl M, “covidarm”: a reaction to the Moderna vaccine, jaad Case Rep 2021; 10:92-5. doi: 10.1016/j.jdcr.2021.02.014.

  53. Bekkali N, Allard T, Lengellé C y Estève E, Éruption eczématiforme après le vaccin par Pfizer-BioNTech covid-19, Therapie 2021; 76(4):364-5.

  54. Alijotas-Reig J, Fernández-Figueras MT y Puig L, Inflammatory, immune- mediated adverse reactions related to soft tissue dermal fillers, Semin Arthritis Rheum, 2013; 43(2):241-58.

  55. Alijotas-Reig J, Fernández-Figueras MT y Puig L, Late-onset inflammatory adverse reactions related to soft tissue filler injections, Clin Rev Allergy Immunol 2013; 45(1):97-108. doi: 10.1007/s12016-012-8348-5.

  56. Bostan E y Yalici-Armagan B, Herpes zoster following inactivated covid- 19 vaccine: a coexistence or coincidence?, J Cosmet Dermatol 2021; 20(6):1566-7.

  57. Barrière J y Bondouy M, “covid-arm” and pet/fdg imaging, Bull Cancer 2021; 108(6):668-9.

  58. Psichogiou M, Samarkos M, Mikos N y Hatzakis A, Reactivation of varicella zoster virus after vaccination for sars-cov-2, Vaccines 2021; 9(6):572.

  59. Cines DB y Bussel JB, sars-cov-2 vaccine-induced immune thrombotic thrombocytopenia, N Engl J Med 2021; 384(23):2254-56.

  60. Pishko AM y Cuker A, Thrombosis after vaccination with messenger rna-1273: is this vaccine-induced thrombosis and thrombocytopenia or thrombosis with thrombocytopenia syndrome?, Ann Intern Med 2021; m21-2680. doi: 10.7326/M21-2680.

  61. Farabi B y Atak MF, Isolated maculopapular eruption localized to head and neck: a cutaneous sign of covid-19 infection, Dermatol Ther 2020; 33(6):e14468.

  62. Recalcati S y Fantini F, Chilblain-like lesions during the covid-19 pandemic: early or late sign?, Int J Dermatol 2020; 59(8):e268-9. doi: 10.1111/ijd.14975.

  63. Piccolo V, Neri I, Filippeschi C, Oranges T, Argenziano G, Battarra VC et al., Chilblain-like lesions during covid-19 epidemic: a preliminary study on 63 patients, J Eur Acad Dermatol Venereol 2020; 34(7):e291-3.

  64. Baeck M y Herman A, covid toes: where do we stand with the current evidence?, Int J Infect Dis 2021; 102:53-5.

  65. Suárez-Valle A, Fernández-Nieto D, Diaz-Guimarãens B, Domínguez- Santás M, Carretero I y Pérez-García B, Acro-ischaemia in hospitalized covid-19 patients, J Eur Acad Dermatol Venereol 2020; 34(9):e455-7.

  66. Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C, Takeshita J et al., Pernio-like skin lesions associated with covid-19: a case series of 318 patients from 8 countries, J Am Acad Dermatol 2020; 83(2):486-92.

  67. Kolivras A, Dehavay F, Delplace D, Feoli F, Meiers I, Milone L, Olemans C et al., Coronavirus (covid-19) infection-induced chilblains: a case report with histopathologic findings, jaad Case Rep 2020; 6(6):489-92.

  68. Herman A, Peeters C, Verroken A, Tromme I, Tennstedt D, Marot L, Dachelet C, Gruson D, Hermans C y Baeck M, Evaluation of chilblains as a manifestation of the covid-19 pandemic, jama Dermatol 2020; 156(9):998-1003.

  69. Baeck M, Peeters C y Herman A, Chilblains and covid-19: further evidence against a causal association, J Eur Acad Dermatol Venereol 2021; 35(1):e2-3. doi: 10.1111/jdv.16901.

  70. Feito-Rodríguez M, Mayor-Ibarguren A, Cámara-Hijón C, Montero- Vega D, Servera-Negre G, Ruiz-Bravo E, Nozal P et al., Chilblain-like lesions and covid-19 infection: a prospective observational study at Spain’s ground zero, J Am Acad Dermatol 2021; 84(2):507-9.

  71. Zaladonis A, Huang S y Hsu S, covid toes or pernio?, Clin Dermatol 2020; 38(6):764-7.

  72. Balestri R, Magnano M, Rizzoli L y Rech G, Do we have serological evidences that chilblain-like lesions are related to sars-cov-2? A review of the literature, Dermatol Ther 2020; 33(6):e14229.

  73. Hedou M, Carsuzaa F, Chary E, Hainaut E, Cazenave-Roblot F y Masson Regnault M, Comment on “Cutaneous manifestations in covid-19: a first perspective” by Recalcati S, J Eur Acad Dermatol Venereol 2020; 34(7):e299-e300.

  74. Van Damme C, Berlingin E, Saussez S y Accaputo O, Acute urticaria with pyrexia as the first manifestations of a covid-19 infection, J Eur Acad Dermatol Venereol 2020; 34(7):e300-1. doi: 10.1111/jdv.16523.

  75. Elmas ÖF, Demirbas, A, Özyurt K, Atasoy M y Türsen Ü, Cutaneous manifestations of covid-19: a review of the published literature, Dermatol Ther 2020; 33(4):e13696. doi: 10.1111/dth.13696.

  76. Recalcati S, Cutaneous manifestations in covid-19: a first perspective, J Eur Acad Dermatol Venereol 2020; 34(5):e212-13. doi: 10.1111/jdv.16387.

  77. Marzano AV, Genovese G, Fabbrocini G et al., Varicella-like exanthem as a specific covid-19 associated skin manifestation: multicenter case series of 22 patients, J Am Acad Dermatol 2020; 83(1):280-5. doi: 10.1016/j.jaad.2020.04.044.

  78. Conforti C, Zalaudek I, Giuffrida R, Zorat F, Grillo A, Colapietro N et al., “covid-mask”: an atypical livedoid manifestation of covid-19 observed in a Northern Italy hospital, Dermatol Ther 2020; 33(4):e13701.

  79. Verheyden M, Grosber M, Gutermuth J y Velkeniers B, Relapsing symmetric livedo reticularis in a patient with covid-19 infection, J Eur Acad Dermatol Venereol 2020; 34(11):e684-6.

  80. Manalo IF, Smith MK, Cheeley J y Jacobs R, A dermatologic manifestation of covid-19: transient livedo reticularis, J Am Acad Dermatol 2020; 83(2):700. doi: 10.1016/j.jaad.2020.04.018.

  81. Occidental M, Flaifel A, Lin LH, Guzzetta M, Thomas K y Jour G, Investigating the spectrum of dermatologic manifestations in covid-19 infection in severely ill patients: a series of four cases, J Cutan Pathol 2021; 48(1):110-5.

  82. Tas, kın B, Vural S, Altug˘ E, Demirkesen C, Kocatürk E, Çelebi I . et al., Coronavirus 19 presenting with atypical Sweet’s syndrome, J Eur Acad Dermatol Venereol 2020; 34(10):e534-5.

  83. Tusheva I, Damevska K, Dimitrovska I, Markovska Z y Malinovska- Nikolovska L, Unilateral livedo reticularis in a covid-19 patient: case with fatal outcome, jaad Case Rep 2021; 7:120-1.




2020     |     www.medigraphic.com